Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action

Hu,Baoshan; Meng,Xiangchao; Zhang,Yan; Hossain,Mohammad   Monir; Wu,Lijun; Zhang,Yuanyuan; Peng,Xiaobing; Zhang,Xuepeng

doi:10.3892/or.2018.6237

Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF‑7 cells in vitro and in vivo and its mechanism of action

Authors:
- Baoshan Hu
- Xiangchao Meng
- Yan Zhang
- Mohammad Monir Hossain
- Lijun Wu
- Yuanyuan Zhang
- Xiaobing Peng
- Xuepeng Zhang
View Affiliations

Affiliations: Department of Surgical Oncology, Affiliated Hospital, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China, International Education College, North China University of Science and Technology, Tangshan, Hebei 063000, P.R. China
Published online on: January 26, 2018 https://doi.org/10.3892/or.2018.6237
Pages: 1640-1648
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A disintegrin and metalloprotease 17 (ADAM17) is highly expressed in many malignant tumors and is closely related to their development. We showed in a previous study that silencing of ADAM17 by siRNA inhibited the growth of MCF‑7 breast cancer cells in vitro and in vivo. In the present study, we investigated the effects of ADAM17-short hairpin RNA (ADAM17‑shRNA) on MCF‑7 breast cancer cells and explored the potential action pathway. In vitro, transfection of shRNAs was performed using a lentivirus, and the effects of ADAM17‑shRNA on invasion, proliferation and cell cycle distribution of MCF‑7 cells were assessed by Boyden chamber method, real‑time cell analysis and flow cytometry, respectively. In vivo, MCF‑7 cells with different administrations were transplanted subcutaneously into nude mice, and the effect of ADAM17‑shRNA on the growth of transplanted tumors was assessed. In addition, the morphological structures were observed by H&E staining, and the expression of ADAM17 and Ki‑67 was assessed by immunohistochemistry; expression of ADAM17, EGFR, p‑EGFR, AKT, p‑AKT, ERK and p‑ERK proteins was assessed by western blotting, respectively. Our data showed that ADAM17‑shRNA successfully inhibited ADAM17 mRNA expression, invasion and proliferation of MCF‑7 cells resulting in G0/G1 phase arrest, and significantly inhibited the growth of transplanted tumors with larger areas of necrosis, low expression of ADAM17 and Ki-67 and reduced protein expression of ADAM17, EGFR, p‑EGFR, AKT, p‑AKT, ERK, and p‑ERK in the tumor tissues. The present research suggests that ADAM17‑shRNA can inhibit MCF‑7 cell invasion and proliferation in vitro and inhibit MCF‑7 xenograft growth in vivo through the EGFR/PI3K/AKT and EGFR/MEK/ERK signaling pathways.

View Figures

View References

1	Ghoncheh M, Pournamdar Z and Salehiniya H: Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 17:43–46. 2016. View Article : Google Scholar : PubMed/NCBI
2	Caiazza F, McGowan PM, Mullooly M, Murray A, Synnott N, O'Donovan N, Flanagan L, Tape CJ, Murphy G, Crown J and Duffy MJ: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumor effects in triple-negative breast cancer cells. Br J Cancer. 112:1895–1903. 2015. View Article : Google Scholar : PubMed/NCBI
3	Ocaña A, Amir E, Seruga B, Martin M and Pandiella A: The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treat Rev. 39:68–76. 2013. View Article : Google Scholar : PubMed/NCBI
4	Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, et al: A metalloproteinase-disintegrin that releases tumor-necrosis factor-alpha from cells. Nature. 385:729–733. 1997. View Article : Google Scholar : PubMed/NCBI
5	Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, et al: Cloning of a disintegrin metalloproteinase that processes precursor tumor-necrosis factor-alpha. Nature. 385:733–736. 1997. View Article : Google Scholar : PubMed/NCBI
6	Baumgart A, Seidl S, Vlachou P, Michel L, Mitova N, Schatz N, Specht K, Koch I, Schuster T, Grundler R, et al: ADAM17 regulates epidermal growth factor receptor expression through the activation of Notch1 in non-small cell lung cancer. Cancer Res. 70:5368–5378. 2010. View Article : Google Scholar : PubMed/NCBI
7	Santiago-Josefat B, Esselens C, Bech-Serra JJ and Arribas J: Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J Biol Chem. 282:8325–8331. 2007. View Article : Google Scholar : PubMed/NCBI
8	Murphy G: The ADAMs: Signaling scissors in the tumor microenvironment. Nat Rev Cancer. 8:929–941. 2008. View Article : Google Scholar : PubMed/NCBI
9	Zheng X, Jiang F, Katakowski M, Kalkanis SN, Hong X, Zhang X, Zhang ZG, Yang H and Chopp M: Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 98:674–684. 2007. View Article : Google Scholar : PubMed/NCBI
10	Rego SL, Helms RS and Dréau D: Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunol Res. 58:87–100. 2014. View Article : Google Scholar : PubMed/NCBI
11	Maretzky T, Zhou W, Huang XY and Blobel CP: A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17. Oncogene. 30:611–618. 2011. View Article : Google Scholar : PubMed/NCBI
12	Qin CF, Hao K, Tian XD, Xie XH and Yang YM: Combined effects of EGFR and Hedgehog signaling pathway inhibition on the proliferation and apoptosis of pancreatic cancer cells. Oncol Rep. 28:519–526. 2012. View Article : Google Scholar : PubMed/NCBI
13	Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D and Habib AA: Ligand-independent EGFR signaling. Cancer Res. 75:3436–3441. 2015. View Article : Google Scholar : PubMed/NCBI
14	McGowan PM, Ryan BM, Hill AD, McDermott E, O'Higgins N and Duffy MJ: ADAM-17 expression in breast cancer correlates with variables of tumor progression. Clin Cancer Res. 13:2335–2343. 2007. View Article : Google Scholar : PubMed/NCBI
15	McGowan PM, McKiernan E, Bolster F, Ryan BM, Hill AD, McDermott EW, Evoy D, O'Higgins N, Crown J and Duffy MJ: ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol. 19:1075–1081. 2008. View Article : Google Scholar : PubMed/NCBI
16	Kenny PA: TACE: A new target in epidermal growth factor receptor-dependent tumors. Differentiation. 75:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
17	Meng X, Hu B, Hossain MM, Chen G, Sun Y and Zhang X: ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation. Int J Oncol. 49:682–690. 2016. View Article : Google Scholar : PubMed/NCBI
18	Rose-John S: ADAM17, shedding, TACE as therapeutic targets. Pharmacol Res. 71:19–22. 2013. View Article : Google Scholar : PubMed/NCBI
19	Rao DD, Vorhies JS, Senzer N and Nemunaitis J: siRNA vs. shRNA: Similarities and differences. Adv Drug Deliv Rev. 61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
20	Gvozdeva OV, Prassolov VS, Zenkova MA, Vlassov VV and Chernolovskaya EL: Silencing of inducible immunoproteasome subunit expression by chemically modified siRNA and shRNA. Nucleosides Nucleotides Nucleic Acids. 35:389–403. 2016. View Article : Google Scholar : PubMed/NCBI
21	Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, Sabatini DM, Chen IS, Hahn WC, Sharp PA, et al: Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 9:493–501. 2003. View Article : Google Scholar : PubMed/NCBI
22	Klinghoffer RA, Magnus J, Schelter J, Mehaffey M, Coleman C and Cleary MA: Reduced seed region-based off-target activity with lentivirus-mediated RNAi. RNA. 16:879–884. 2010. View Article : Google Scholar : PubMed/NCBI
23	Wang Y and Lazo JS: Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion. Oncogene. 31:818–827. 2012. View Article : Google Scholar : PubMed/NCBI
24	Zheng X, Jiang F, Katakowski M, Zhang ZG, Lu QE and Chopp M: ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol Ther. 8:1045–1054. 2009. View Article : Google Scholar : PubMed/NCBI
25	Gao MQ, Kim BG, Kang S, Choi YP, Yoon JH and Cho NH: Human breast cancer-associated fibroblasts enhance cancer cell proliferation through increased TGF-alpha cleavage by ADAM17. Cancer Lett. 336:240–246. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yoshioka T, Hosoda M, Yamamoto M, Taguchi K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y and Yamashita H: Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. 22:185–191. 2015. View Article : Google Scholar : PubMed/NCBI
27	Hao S, He ZX, Yu KD, Yang WT and Shao ZM: New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. Oncotarget. 7:24824–24831. 2016. View Article : Google Scholar : PubMed/NCBI
28	Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, Huang O, He JR, Chen W, Li Y, et al: Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget. 7:31079–31087. 2016.PubMed/NCBI
29	Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
30	Tomas A, Futter CE and Eden ER: EGF receptor trafficking: Consequences for signaling and cancer. Trends Cell Biol. 24:26–34. 2014. View Article : Google Scholar : PubMed/NCBI
31	Li X, Wang Q, Fu L, Liu M and Yu X: Expression of PTEN, p53, and EGFR in the molecular subtypes of breast carcinoma and the correlation among them. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 40:973–978. 2015.(In Chinese). PubMed/NCBI
32	Lluch A, Eroles P and Perez-Fidalgo JA: Emerging EGFR antagonists for breast cancer. Expert Opin Emerg Drugs. 19:165–181. 2014. View Article : Google Scholar : PubMed/NCBI
33	Howe LR and Brown PH: Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res. 4:1149–1157. 2011. View Article : Google Scholar
34	Kim S, Lee J, Oh SJ, Nam SJ and Lee JE: Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Oncol Rep. 34:1613–1619. 2015. View Article : Google Scholar : PubMed/NCBI
35	Xiao LJ, Lin P, Lin F, Liu X, Qin W, Zou HF, Guo L, Liu W, Wang SJ and Yu XG: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol. 40:1714–1724. 2012.PubMed/NCBI
36	Hers I, Vincent EE and Tavare JM: Akt signalling in health and disease. Cell Signal. 23:1515–1527. 2011. View Article : Google Scholar : PubMed/NCBI
37	Toker A and Marmiroli S: Signaling specificity in the Akt pathway in biology and disease. Adv Biol Regul. 55:28–38. 2014. View Article : Google Scholar : PubMed/NCBI
38	Martini M, De Santis MC, Braccini L, Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
39	Dobashi Y, Tsubochi H, Matsubara H, Inoue J, Inazawa J, Endo S and Ooi A: Diverse involvement of isoforms and gene aberrations of Akt in human lung carcinomas. Cancer Sci. 106:772–781. 2015. View Article : Google Scholar : PubMed/NCBI
40	Dobashi Y, Sato E, Oda Y, Inazawa J and Ooi A: Significance of Akt activation and AKT gene increases in soft tissue tumors. Hum Pathol. 45:127–136. 2014. View Article : Google Scholar : PubMed/NCBI
41	Won JK, Yang HW, Shin SY, Lee JH, Heo WD and Cho KH: The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor. J Mol Cell Biol. 4:153–163. 2012. View Article : Google Scholar : PubMed/NCBI
42	Saini KS, Loi S, de Azambuja E, Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and Piccart-Gebhart MJ: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat Rev. 39:935–946. 2013. View Article : Google Scholar : PubMed/NCBI
43	Takai M, Nakagawa T, Tanabe A, Terai Y, Ohmichi M and Asahi M: Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma. Cancer Biol Ther. 16:325–335. 2015. View Article : Google Scholar : PubMed/NCBI
44	Djukom C, Porro LJ, Mrazek A, Townsend CM Jr, Hellmich MR and Chao C: Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression. Pancreas. 43:88–92. 2014. View Article : Google Scholar : PubMed/NCBI
45	Tandon M, Chen Z and Pratap J: Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells. J Cell Biochem. 115:2208–2217. 2014. View Article : Google Scholar : PubMed/NCBI
46	Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, et al: In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res. 15:4649–4664. 2009. View Article : Google Scholar : PubMed/NCBI
47	Xu C, Sun X, Qin S, Wang H, Zheng Z, Xu S, Luo G, Liu P, Liu J, Du N, et al: Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells. Cell Cycle. 14:1686–1697. 2015. View Article : Google Scholar : PubMed/NCBI
48	Hung AC, Tsai CH, Hou MF, Chang WL, Wang CH, Lee YC, Ko A, Hu SC, Chang FR, Hsieh PW and Yuan SS: The synthetic β-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway. Cancer Lett. 371:251–261. 2016. View Article : Google Scholar : PubMed/NCBI
49	Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V, Igelmann S, Mallette FA, Saba-El-Leil MK, Meloche S, et al: Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 27:900–915. 2013. View Article : Google Scholar : PubMed/NCBI
50	Santarpia L, Lippman SM and El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:103–119. 2012. View Article : Google Scholar : PubMed/NCBI
51	Zhang XM, Li BL, Song M and Song JY: Expression and significance of ERK protein in human breast carcinoma. Chin J Cancer Res. 16:269–273. 2004. View Article : Google Scholar
52	Beck Gooz M, Maldonado EN, Dang Y, Amria MY, Higashiyama S, Abboud HE, Lemasters JJ and Bell PD: ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease. Am J Physiol Renal Physiol. 307:F551–F559. 2014. View Article : Google Scholar : PubMed/NCBI